Phase-rectified signal averaging method to predict perinatal outcome in infants with very preterm fetal growth restriction- a secondary analysis of TRUFFLE-trial by Lobmaier, SM et al.
1 
 
 
 
Title page 
 
Phase-rectified signal averaging method to predict perinatal outcome in infants 
with very preterm fetal growth restriction- a secondary analysis of TRUFFLE-trial 
 
Silvia M. LOBMAIER, MD, Nico MENSING VAN CHARANTE, MD, Enrico FERRAZZI, Prof., Dino 
A. GIUSSANI, Prof., Caroline J. SHAW, MD, Alexander MÜLLER, MSc, Javier U. ORTIZ, MD, 
Eva OSTERMAYER, MD, Bernhard HALLER, MSc, Federico PREFUMO, MD, Tiziana 
FRUSCA, MD, Kurt HECHER, Prof., Birgit ARABIN, Prof., Baskaran THILAGANATHAN, Prof., 
Aris T. PAPAGEORGHIOU, MD, Amarnath BHIDE, MD, Pasquale MARTINELLI, Prof., 
Johannes J. DUVEKOT, MD, Jim VAN EYCK, MD, Gerard H.A. VISSER, Prof., Georg 
SCHMIDT, Prof., Wessel GANZEVOORT, MD, Christoph C LEES, MD, Karl T.M. SCHNEIDER, 
Prof., and TRUFFLE investigators* 
 
*TRUFFLE investigators: Caterina M. BILARDO (Amsterdam/Groningen), Christoph 
BREZINKA (Innsbruck), Anke DIEMERT (Hamburg), Jan B. DERKS (Utrecht), Dietmar 
SCHLEMBACH (Graz/Jena), Tullia TODROS (Turin),  Adriana VALCAMONICO (Brescia), Neil 
MARLOW (London), Aleid van WASSENAER-LEEMHUIS (Amsterdam) 
 
We would like to publish Table 2 in the print issue. 
 
Frauenklinik und Poliklinik, Technische Universität München, Munich, Germany (SM 
Lobmaier, JU Ortiz, E Ostermayer, KTM Schneider) 
Department of Obstetrics and Gynecology, Academic Medical Centre Amsterdam, 
Netherlands (N Mensing van Charante, W Ganzevoort) 
Children´s Hospital Buzzi, University of Milan, Milan, Italy (E Ferrazzi) 
Department of Physiology, Development and Neuroscience, University of Cambridge, 
Cambridge, UK (DA Giussani) 
Department of Surgery and Cancer, Imperial College London, London, UK (CJ Shaw, 
CC Lees) 
2 
 
 
 
1. Medizinische Klinik und Deutsches Herzzentrum München der Technischen 
Universität München, Munich, Germany (A Müller, G Schmidt) 
Institute for Medical Statistics and Epidemiology (IMSE), Klinikum rechts der Isar der 
Technischen Universität München, Munich, Germany (B Haller) 
Maternal-Fetal Medicine Unit, University of Brescia, Brescia, Italy (F Prefumo, T 
Frusca) 
Department of Obstetrics and Fetal Medicine, University Medical Center, Hamburg-
Eppendorf, Germany (K Hecher) 
Department of Perinatology, Isala Clinics, Zwolle, Overijssel, Netherlands (B Arabin, J 
van Eyck) 
Fetal Medicine Unit, St George's Hospital, St George's University of London, London, 
United Kingdom (B Thilaganathan, AT Papageorghiou, A Bhide) 
Department of Neuroscience, Reproductive Science and Dentistry, University of 
Naples Federico II, Napoli, Italy (P Martinelli) 
Department of Obstetrics and Gynaecology, Erasmus MC, Rotterdam, Netherlands (JJ 
Duvekot) 
Department of Perinatal Medicine, University Medical Center, Utrecht, Netherlands 
(GHA Visser) 
Department of Development and Regeneration, KU Leuven, Leuven, Belgium (CC 
Lees) 
 
Conflict of interests: CCL is supported by the UK National Institute for Health Research 
(NIHR) Biomedical Research Centre based at Imperial College Healthcare National 
Health Service Trust and Imperial College London. The views expressed are those of 
the authors and not necessarily those of the NHS, the NIHR, or the Department of 
Health. All other authors declare no competing interests. G. Schmidt holds a patent on 
the PRSA technology. 
 
Acknowledgment of financial support: TRUFFLE was supported by ZonMw, 2509 AE 
Den Haag, Netherlands (Grant Number 94506556) in the Netherlands. In other 
3 
 
 
 
countries, the study was not funded. A contribution was made to study funding from 
the Dr Hans Ludwig Geisenhofer Foundation, Munich, Germany. 
Corresponding author:  
Silvia M. Lobmaier 
Ismaninger Str. 22 
D- 81675 München (Germany) 
Telefone number: +49 89 4140 5417 
Fax: +49 89 4140 4892 
Email: silvia.lobmaier@tum.de 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Word count abstract: 359 words 
Word count main text: 2499 words  
4 
 
 
 
Condensation: We performed a secondary analysis of TRUFFLE trial CTG data to 
determine the longitudinal progression and prognostic accuracy of phase-rectified 
signal averaging indices in severely growth restricted fetuses. 
 
Short title: Phase-rectified signal averaging method applied to TRUFFLE raw data  
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Abstract 
Background: Phase-rectified signal averaging, an innovative signal processing 
technique, can be used to investigate quasi-periodic oscillations in noisy, non-
stationary signals obtained from fetal heart rate. Phase-rectified signal averaging is 
currently the best method to predict survival after myocardial infarction in adult 
cardiology. Application of this method to fetal medicine has established significantly 
better identification than with short term variation by computerized cardiotocography of 
growth restricted fetuses.  
Objective: The aim of this study was to determine the longitudinal progression of 
phase-rectified signal averaging indices in severely growth restricted human fetuses 
and the prognostic accuracy of the technique in relation to perinatal and neurological 
outcome. 
Study design: Raw data from cardiotocography monitoring of 279 human fetuses were 
obtained from eight centers taking part in the multicenter European “TRUFFLE” trial 
on optimal timing of delivery in fetal growth restriction. Average acceleration and 
deceleration capacities were calculated by phase-rectified signal averaging to 
establish progression from 5 days to 1 day prior to delivery and compared with short 
term variation progression. The receiver operating characteristic curves of average 
acceleration and deceleration capacities and short term variation were calculated and 
compared between techniques for short- and intermediate-term outcome.  
Results: Average acceleration and deceleration capacities and short term variation 
showed a progressive decrease in their diagnostic indices of fetal health from the first 
exam five days prior to delivery to one day before delivery. However, this decrease 
was significant three days before delivery for average acceleration and deceleration 
capacities, but two days before delivery for short term variation. Compared with 
analysis of changes in short term variation, analysis of (delta) average acceleration 
and deceleration capacities better predicted   values of Apgar<7 as well as antenatal 
death (area under the curve for prediction of antenatal death: delta average 
acceleration capacity .62 (.19 - 1.0 confidence interval), delta short term variation .54 
(.13 - .97), p=.006; area under the curve for prediction Apgar<7: average deceleration 
capacity <24h before delivery .64 (.52 - .76 confidence interval), short term variation 
<24h before delivery .53 (.40 - .65), p=.015). Neither phase-rectified signal averaging 
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indices nor short term variation showed predictive power for developmental disability 
at 2 years of age (Bayley developmental quotient < 95 or < 85).  
Conclusion: Phase-rectified signal averaging method seems to be at least as good as 
short term variation to monitor progressive deterioration of severely growth restricted 
fetuses. Our findings suggest that for short term outcomes such as Apgar score, 
phase-rectified signal averaging indices could even be a better test than short term 
variation. Overall our findings confirm the possible value of prospective trials based on 
phase-rectified signal averaging indices of autonomic nervous system of severely 
growth restricted fetuses. 
   
 
Key words: fetal growth restriction, FGR, intrauterine growth restriction, IUGR, short- 
term variation, STV, phase-rectified signal averaging, PRSA, CTG, 
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Introduction 
The variability in heart rate is determined by several mechanisms including opposing 
sympathetic and vagal influences of the autonomic nervous system in addition to 
respiratory, baroreflex and circadian processes 1. Its analysis has long been 
established as a useful predictor of cardiovascular health in the fetal, newborn and 
adult periods 2,3. Human fetuses affected with severe growth restriction show a 
decrease in fetal heart rate (FHR) variability. Short term variation (STV), a calculated 
measure designed to make assessment of FHR variability quantitative, has proven 
predictive of fetal distress in the antenatal setting. Values for STV below 2.6 ms are 
known to be highly associated with fetal metabolic acidaemia (defined as umbilical 
artery base deficit greater than 12 mmol/L) and/or intrauterine death whereas STV 
values above 3 ms are rarely associated with adverse outcome 4.  
In contrast to other methods of analysis of FHR variability, phase-rectified signal 
averaging (PRSA) permits the detection of quasi-periodicities in non-stationary, noisy 
variables, typical signals represented by the heart rate, thereby allowing complex 
oscillatory modulations of multiple frequency drivers to be determined, rather than 
simply describing the degree of variability from the baseline. PRSA predicts survival 
after myocardial infarction in adult cardiology 5 and it has been successfully 
investigated in fetal medicine 6, despite the challenges of a non-stationary signal, with 
more interference in the signal obtained than the post-infarct adult. PRSA, in short, 
calculates not only the variation of the fetal heart rate, but the speed of changes in fetal 
heart rate, described as the average acceleration (AAC) and deceleration (ADC) 
capacities. The novel parameter AAC better differentiates growth restricted fetuses 
from controls than analysis by STV 6-8. Accurate prediction of fetal growth restriction 
by PRSA analysis has also been confirmed by investigators comparing data both from 
Doppler 9,10 and trans-abdominal fetal ECG 11,12 signals.  
Even acute intra-partum hypoxia might be better predicted using PRSA than STV 13-15 
analysis. Therefore, analysis of alterations in FHR by PRSA holds potential in 
predicting value of acute as well as chronic fetal hypoxia in complicated pregnancy. 
However, this has not been tested systematically in large cohorts.  
The most comprehensive, multi-center study of human early fetal growth restriction 
(FGR) is the Trial of Umbilical and Fetal Flow in Europe (TRUFFLE) 16. In TRUFFLE, 
more than 500 pregnancies were monitored for fetal health surveillance using Doppler 
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indices in the ductus venosus or STV determined by computerized cardiotocography 
(c-CTG). Perinatal outcome as well as intermediate neurological outcome at two years 
of age were also determined.  The aim of this study was to apply PRSA analysis to 
FHR data obtained from the TRUFFLE cohort to compare for first time the longitudinal 
changes ofPRSA and STV and the prognostic value for  predicting adverse perinatal 
and neurological outcome in severely growth restricted human fetuses.  
 
Materials and Methods 
The TRUFFLE clinical trial was a prospective, multicenter randomized study performed 
in five European countries and 20 tertiary care centers. Women were eligible for 
inclusion if they had a singleton pregnancy between 26 and 31+6 weeks of gestation 
affected by fetal growth restriction defined as a fetal abdominal circumference below 
the 10th percentile and abnormal umbilical artery Doppler with a pulsatility index (PI) 
above the 95th percentile. Exclusion criteria were ultrasound appearances suggestive 
of congenital fetal abnormality, abnormal karyotype on invasive testing or women 
younger than 18 years of age. The study protocol was approved by the institutional 
ethics committee and patients provided written informed consent. Participants were 
randomly assigned to one of three groups (c-CTG STV reduction, early or late ductus 
venous changes) to establish the timing of delivery. Baseline maternal and fetal 
characteristics were collected at study entry.   
In the CTG randomization arm the timing of delivery was decided on the following cut-
off values: STV < 3.5 ms at < 29 weeks of gestation or STV < 4 ms at ≥ 29 weeks of 
gestation. In cases where maternal corticosteroids were given to accelerate fetal lung 
maturation, no decision regarding delivery was made on the grounds of reduced STV 
up to 72h after the first intramuscular dose, as maternal corticosteroids are known to 
produce short term reductions in FHR variability 17-20. Monitoring in all three groups 
included umbilical artery Doppler and c-CTG was recommended at least once a week.  
However, most centers performed c-CTGs more frequently, subject to local policies. 
“Safety net” criteria, which prompted delivery regardless of any other measures, 
including spontaneous fetal heart rate decelerations, or assigned to a study group with 
a STV < 2.6 ms at 26+0 - 28+6 weeks or STV < 3 ms at ≥ 29 weeks of gestation. 
Furthermore, delivery was recommended if reversed umbilical artery end diastolic flow 
occurred ≥ 30 weeks of gestation or if there was absent umbilical artery end diastolic 
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flow at ≥ 32 weeks gestation. Further details about the study protocol can be derived 
from the original publication 16. 
All participating centers were invited to provide c-CTG raw data for this secondary 
analysis, and all registrations available in the five days preceding delivery or antenatal 
fetal death were selected for inclusion. Therefore four time windows were selected. 
From all participating centers, eight of twenty were able to provide appropriate c-CTG 
raw data (Amsterdam, Brescia, Hamburg, London, Munich, Naples, Rotterdam, 
Zwolle). The complete c-CTG signal was used for analysis. According to protocol c-
CTGs were recorded using Sonicaid System 8002 (Oxford Instruments Medical Ltd, 
Surrey, UK). Data were analyzed directly for STV using the original Dawes/Redman 
algorithm  21,23 and by the PRSA method for AAC and ADC calculation previously 
described in detail by Lobmaier et al. 6. For PRSA, data were analyzed off-line after 
computer download, and the following parameters were used: T = 10 samples, L = 100 
samples, anchor points were defined as increases (AAC) or decreases (ADC) <5%. 
CTG data do not reflect real beat-to-beat heart rates. CTG technique works with a 
sample frequency of 4 Hz. That means that 4 times per second the fetal heart rate is 
detected by ultrasound, so, the used filter of T = 10 samples corresponds to 2,5 
seconds and T= 100 samples to 25 seconds. Not all centers disposed of a computer 
connected to the CTG device. That´s the reason for missing CTG raw data from the 
centers not providing data. 
Delta (Δ) values of AAC, ADC and STV were calculated, taking the difference between 
first (5-4 days prior to delivery) and last (<24h prior to delivery) value before delivery 
or intrauterine fetal death. 
Statistical analysis was performed using SPSS for Windows (version 22.0, SPSS Inc., 
Chicago, IL, USA) and R (version 3.2.2, R Core Team (2015). R: A language and 
environment for statistical computing. R Foundation for Statistical Computing, Vienna, 
Austria. URL https://www.R-project.org/). For comparison of mean values at different 
time points an analysis of variance for repeated measurements was performed. If a 
significant change of mean values over time was observed in the ANOVA, Student’s t- 
test for paired data was used for comparison of consecutive time points and for a 
comparison of the first (5-4 days before delivery) to the last (within 24 hours before 
delivery) measurement. The diagnostic effectiveness of the different c-CTG 
parameters for outcome prediction was analyzed using the area under the receiver 
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operating characteristic (ROC) curve (AUC). Confidence intervals for the AUCs were 
estimated based on 2000 bootstrap samples, each. Comparisons between AUCs was 
performed using the test proposed by Hanley et al. 24, with standard deviation of the 
difference between the AUCs estimated from 2000 bootstrap samples. The function 
roc.test provided in the R library pROC 25 was used therefore. All statistical 
comparisons were conducted two-sided and a p value <0.05 was considered 
statistically significant. 
 
Results 
A total of 279 fetuses and 947 c-CTG records (3.4 CTG records per fetus) were 
available for secondary analysis for this study. From one center (Rotterdam) STV data 
could not be extracted for technical reasons, so that only PRSA indices were available 
for Rotterdam patients. Data for the study population demographic characteristics, 
obstetric and neonatal outcome are summarized in Table 1. Considering adverse 
outcomes, 11.1% of the neonates had a 5- minute Apgar below 7 and 3.2% had an 
umbilical artery pH below 7.1, suggestive of poor condition at birth in these infants. A 
Bayley score developmental quotient (DQ) < 95 was observed in 22.9% and a score 
below 85 in 5.0% at the two years follow-up, suggestive of moderate developmental 
disability in these infants.  
Mean values of AAC, ADC and STV at 4 different time points (5-4 days prior to delivery, 
72-48 h, 48-24 h, <24 h) were calculated and compared as displayed in Figure 1. At 5-
4 days compared to <24 h prior to delivery AAC was reduced from 1.97 (SD 0.39) to 
1.69 (0.45), ADC from 1.95 (0.40) to 1.69 (0.48) and STV from 6.07 (2.14) to 4.71 
(2.14). Although a progressive decrease in all three indices of fetal health was obtained 
towards delivery, the decrease for AAC and ADC became significant 72 hours prior to 
performed delivery, while the decrease in STV became statistically significant < 48 h 
prior to delivery. 
The area under the ROC curve (AUC) value was calculated for each main perinatal 
outcome. Table 2 shows the results of the ROC curve comparisons considering the 
delta values for each variable between the 5-4 days to 24 hours prior to delivery time 
interval or using the last index within 24 h prior to delivery. Although changes in AAC 
and ADC showed a general trend towards better predictive performance for adverse 
outcomes than STV, this was significant only for ∆AAC in the prediction of antenatal 
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death and for ADC in the 24 h before delivery to predict an Apgar score < 7. Neither 
∆AAC, ∆ADC, ∆STV nor AAC, ADC or STV in the last 24 h before delivery showed 
predictive power for developmental disability at 2 years of age (Bayley DQ < 95 or < 
85).  
 
Comment 
The aim of this study based on data obtained from severely growth restricted human 
fetuses in the TRUFFLE study was to assess the predictive value of average 
acceleration and deceleration capacities (AAC, ADC) calculated by phase-rectified 
signal averaging (PRSA) analysis compared to heart rate short term variation (STV) 
measured by computerized CTG (c-CTG). 
The main finding of this analysis is represented by the longitudinal progression of AAC 
and ADC compared with STV. All three parameters showed a decrease in their 
diagnostic indices from the first exam, five days prior to delivery to one day before 
delivery. However, this decrease became statistically significant three days prior to 
delivery for AAC and ADC, and two days prior to delivery for STV. Comparing these 
data to published reference curves we can see that these changes seem to be due to 
impairment of the intrauterine situation. In healthy fetuses AAC and ADC remain 
relatively constant during pregnancy 8. PRSA method proved not only to compare well 
with a standard of care such as STV, but to yield even earlier signs of a worsening 
control of cardiovascular function by fetal autonomic nervous system (ANS).  
Further, fetuses with more pronounced decrements from baseline in AAC and ADC as 
measured by greater ∆AAC and ∆ADC showed a tendency for increased risk for 
adverse perinatal outcome. Areas under the Receiver Operator Curves (ROC) of 
PRSA indices were significantly higher for the Apgar score <7 and antenatal death 
compared to conventional c-CTG calculation.  
The analysis in the present study has some limitations. The total number of adverse 
events in this study was not very high 26, thereby limiting the precision of the estimated 
measures of prognostic accuracy of the results regarding perinatal outcome. 
Furthermore, raw data were available in a subset of 279 out of 503 TRUFFLE patients.  
The PRSA derived indices AAC and ADC describe the speed of changes in fetal heart 
rate, triggered by sympathetic and vagal branches, reflecting fetal ANS capacity. 
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Although changes in STV, and now PRSA, have been demonstrated signal 
deteriorating fetal condition, the corresponding changes in the developing fetal ANS 
that underlie this reduction in heart rate variability have not been fully elucidated. It is 
well established from data derived from human pregnancy 13-15 and from animal models 
15,27,28 that acute fetal hypoxia leads to activation of the fetal ANS. For instance, acute 
fetal hypoxia in ovine pregnancy leads to an elevation in fetal plasma catecholamine 
levels 29, increased fetal renal sympathetic nerve discharge  30 and fetal treatment with 
sympathetic antagonists markedly impairs fetal cardiovascular responses to acute 
hypoxia 31,32. Conversely, the effect of chronic fetal hypoxia on fetal sympathetic activity 
is less clear. However, accumulated evidence is beginning to suggest that chronic fetal 
hypoxia leads to marked alterations in sympathetic ANS activity. For instance, two 
studies have reported elevated basal values and alterations in the developmental 
decline of fetal heart rate with advancing gestation in the chronically hypoxic sheep 
fetus 33,34.  
One very recent study of in vivo continuous wireless recording of fetal cardiovascular 
function in fetal sheep exposed to significant chronic hypoxia for 10 days in late 
gestation confirmed a delayed fall in fetal heart rate with advancing gestation 34.   
In contrast, acute fetal hypoxia causes an immediate increase in short-term fetal heart 
rate variation followed by a gradual decrease when fetal hypoxia becomes chronic 35. 
The initial increase in FHR variability is likely caused by the increase of fetal plasma 
catecholamine concentration 30 but heart rate variability decreases in spite of persistent 
elevations in fetal plasma norepinephrine and arterial blood pressure during chronic 
hypoxia  35. Murotsuki et al. hypothesized that chronic fetal hypoxia might alter the 
normal maturational control of fetal heart rate and its variability. Data of wireless 
recording of fetal cardiovascular function in fetal sheep exposed to significant chronic 
hypoxia for 10 days in late gestation is in keeping with this hypothesis. Shaw et al. 36 
reported that in normoxic pregnancy the fetal heart rate decreased and SDNN (an 
index of total fetal heart rate variability) increased with advancing gestation. 
Conversely, advancing gestation in hypoxic pregnancy led to a greater fall in fetal heart 
rate, a decrease in sympathetic activity, and a loss of total heart rate variation.  
Therefore, chronic significant fetal hypoxia appears to be associated with a loss of total 
power and increased parasympathetic dominance in the fetal heart rate variation 
power spectra 36. Temporary reductions in STV have been linked with decreased 
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sympathetic control of FHR variability 37 and reductions in the sympathetic control of 
FHR variability have been observed in chronically hypoxic and growth restricted human 
fetuses 38, although no evaluation of STV was made in these studies. Rivolta et al. 15 
reported the first in vivo evaluation of PRSA on FHR analysis in late gestation fetal 
sheep: acute fetal hypoxia led to an increase in the AAC and ADC values, confirming 
activation of the fetal ANS by PRSA. Data in the present study show that fetal growth 
restriction in human pregnancy is associated with a progressive fall in AAC and ADC 
values. This finding is not only in keeping with the chronically hypoxic sheep fetus 
showing impaired or perhaps exhausted activation of the sympathetic component of 
the ANS influences on fetal heart rate variation 36, but it highlights that PRSA may be 
useful in predicting fetal deterioration associated with chronic fetal hypoxia. In this 
context, it is interesting that PRSA predicted earlier deterioration of fetal health 
associated with adverse outcome than STV. It is possible that the use of PRSA to 
quantify the speedof changes in the fetal heart rate could indicate reduced 
responsiveness of the sympathetic nervous system.  This would precede exhaustion 
of sympathetic nervous control and acute reduction in STV, as in our data, however 
this remains conjecture. 
These findings cast a stronger link between cardiovascular and neuroendocrine 
damages in fetal life and cardiovascular events later in adult life 39,40. Long term follow-
up studies could prove or disprove the possible role of PRSA as a better predictor of 
impaired cardiovascular outcome at later age. On the other hand PRSA analysis might 
be of interest in other population like pregnancies affected by gestational diabetes.  
These fetuses are at high risk for developing hypertension in later life and PRSA might 
help to identify those fetuses. 
 
In summary, analysis of fetal heart rate by PRSA identifies progressive cardiovascular 
dysfunction in severely growth restricted human fetuses slightly earlier than STV. 
These data suggest that further investigation of the value and implementation of PRSA 
in monitoring fetal health in human clinical practice is warranted, perhaps with a 
particular relevance for alterations in autonomic nervous system function in severely 
growth restricted human fetuses.  
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Table 1: Study population characteristics. Data are reported as number and 
percentage in brackets, and as mean and SD in brackets. 
 
Study population : Total n=279 
Demographic and clinical characteristics:   
Mean maternal age (years) 30.5 (5.6) 
Caucasian ethnicity 221 (79.2%) 
Nulliparous 174 (62.4%) 
Mean BMI (kg/m²) 25.4 (6.0) 
Smoking 50 (17.9%) 
Diabetes 2 (0.7%) 
Chronic hypertension 28 (10.0%) 
Renal morbidity 5 (1.8%) 
Other medical disease 46 (16.5%) 
Any gestational hypertensive disease  53 (19.0%) 
Pre-eclampsia/HELLP 122 (43.7%) 
Mean gestational age at entry (weeks) 29.1 (10.5) 
Mean EFW by ultrasound (grams) 886.2 (210.1) 
Mean UA PI 2.01 (0.58) 
Umbilical artery AREDF 111 (39.8%) 
Mean U/C ratio 1.48 (0.61) 
Mean DV PI 0.60 (0.02) 
  
Obstetric outcome:   
Mean GA at delivery (weeks) 30.6 (2.0) 
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Mean interval to delivery (days) 10.2 (10.2) 
Cesarean delivery 272 (97.5%) 
Mean birthweight (grams) 1000.8 (280.9) 
Male sex 137 (49.1%) 
Apgar score <7 31 (11.1%) 
UA pH 
 
Data available 202 (72.4%) 
Mean pH 7.26 (0.08) 
<7.0 4 (1.4%) 
<7.1 9 (3.2%) 
  
Neonatal outcome:   
Livebirth 255 (91.4%) 
Neonatal death 18 (6.4%) 
Antenatal death 6 (2.2%) 
Bayley III test performed 219 (78.5%) 
DQ<85 14 (5.0%) 
DQ<95 60 (22.9%) 
  
  
EFW: estimated fetal weight; UA: umbilical artery; PI: pulsatility index; AREDF: 
Absent or reversed end diastolic ﬂow; U/C ratio: umbilical artery pulsatility 
index to median cerebral artery pulsatility index ratio; DV: ductus venosus; GA: 
gestational age; DQ: developmental quotient 
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Table 2: Comparison of Areas under the ROC (AUC) for indices of fetal heart rate variability. AUC and 95% confidence interval in 
brackets 
 
 ∆AAC ∆ADC ∆STV AAC1 ADC1 STV1 
Apgar < 7 .67 (.50-.82) .64 (.47-.79) .61 (.43-.78) .63 (.49-.76) .64 (.52-.76)* .53 (.40-.65) 
pH < 7.1 .72 (.40-.95) .71 (.38-.96) .70 (.40-.96) .68 (.45-.88) .68 (.44-.90) .74 (.56-.89) 
Antenatal death .62 (.19-.1.0)* .54 (.06-.1.0) .56 (.13-.97) .72 (.40-.96) .72 (.38-.95) .51 (.28-.86) 
       
∆ = AUC obtained for each parameter when differences between first CTG available (5-4 days prior to delivery) and last CTG (within 24 
hours prior to delivery). Only cases with valid AAC, ADC AND STV values were compared. 
1 = AUC obtained for each parameter within 24h prior to delivery 
*  =  significant difference at p<0.05 versus STV
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Figure legend 
 
Title: Longitudinal progression of phase-rectified signal averaging and computerized 
cardiotocography indices. Figure 1 a-c: Longitudinal changes of average acceleration 
capacity (AAC) (a), average deceleration capacity (ADC) (b) and short term variation 
(STV) (c) during the 5 days prior to delivery or intrauterine death.  
 
